Access Article Clinical Trials Events 
Project CBD
FEBRUARY 28, 2023
9 In a February 2021 article in Nutritional Outlook , Jesse Karagianes, vice president of sales of the CBD natural products company CV Sciences (San Diego, California), was quoted as saying: “[T]he single largest factor which contributed to slow category sales was the deluge of inferior products hitting the market. Accessed July 25, 2021.
Veriheal
MAY 3, 2022
a necessary question to address as medical marijuana becomes more accessible. Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 22, 2021
Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. the CBD, CBG or THC compounds).
SpeedWeed
JULY 6, 2021
By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”. The project also intends to advance research into how psychedelics can heal trauma and how to ensure equitable access to these therapies. View original article.
TheAnswerPage
JANUARY 11, 2022
As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Le-Short C.,
Cannabis Law Report
DECEMBER 7, 2021
Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. Stolar & Ilan Matok. 1), 95%CI [??1.39–(??0.60)])
MMJ Recs
JULY 11, 2024
In this article, we explore the role of medical marijuana in addressing insomnia, examining its effectiveness, safety considerations, legal aspects, and practical considerations for patients and healthcare providers. It is often caused by life events such as stress, anxiety, or a significant change in routine.
Expert insights. Personalized for you.
144 
Let's personalize your content